Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 October 2024
Summary of opinion: Tevimbra, 17/10/2024 Positive
Summary of opinion: Hepcludex, 17/10/2024 Positive
Summary of opinion: Cerdelga, 17/10/2024 Positive
Summary of opinion: Kevzara Positive
Summary of opinion: Yselty, 17/10/2024 Positive
Translarna: EMA re-confirms non-renewal of authorisation of Duchenne muscular dystrophy medicine
Summary of opinion: Tevimbra, 17/10/2024 Positive
Summary of opinion: Kisqali, 17/10/2024 Positive
Human medicines European public assessment report (EPAR): Zytiga, abiraterone, Date of authorisation: 05/09/2011, Revision: 28, Status: Authorised